Primary central nervous system post-transplant lymphoproliferative disorders: the spectrum of imaging appearances and differential

Matthew L. White1*, Drew W. Moore1, Yan Zhang1, Keiper D. Mark1, Timothy C. Greiner2 and Philip J. Bierman3

Abstract
Objective: Central nervous system post-transplant lymphoproliferative disorder (CNS-PTLD) is a rare disease that presents with non-specific signs and symptoms. The purpose of this article is to present the imaging appearances of CNS-PTLD by magnetic resonance imaging. We highlight the differential diagnostic considerations including primary central nervous system lymphoma, glioblastoma, cerebral abscess, and metastatic disease. This is an important topic to review since in daily practice the diagnosis of CNS-PTLD is often not initially considered when present due to its rarity and the lack of radiologists’ familiarity with the disease.

Conclusion: Knowing the unique imaging features of CNS-PTLD narrows the differential diagnosis, facilitates the diagnostic work-up, and optimizes making the diagnosis. Advanced MRI data for CNS PTLD is limited but is promising for helping with narrowing the differential diagnosis.

Keywords: Central nervous system, Post-transplant lymphoproliferative disorders, MRI, CT, Clinical features

Key points
- There is a tendency for CNS-PTLD lesions to be ring enhancing, have ill-defined enhancing margins, multifocal, supratentorial, and lobar in location.
- The solid areas of CNS-PTLD lesions often have restricted diffusion likely related to hypercellularity.
- Perfusion analysis would demonstrate a lower maximum relative cerebral blood volume in CNS-PTLD.
- CNS-PTLD shares conventional imaging characteristics with multiple other disease processes including PCNS lymphoma, GBM, metastatic disease, abscess, and other infections.
- It is important to know the clinical history and to consider the diagnosis of CNS-PTLD to facilitate the diagnosis.

Central nervous system post-transplant lymphoproliferative disorder (CNS-PTLD) is a rare disorder due to immunosuppression secondary to solid organ, stem cell, or bone marrow transplantation [1, 2]. Cases begin to appear as early as 6 weeks in the first year after transplantation but most cases take years to present after transplantation and the attendant immunosuppression. Viral factors have been strongly associated with CNS-PTLD and the strongest association is with Epstein-Barr virus (EBV). The neurological symptoms that patients present with are quite variable. The symptoms are related to general neurological dysfunction as well as specific signs and symptoms related to the location of the CNS lesion. Early consideration for CNS-PTLD is paramount to institute an appropriate work-up and to determine the needed therapy. Since an early step in the work-up is often neuroimaging, a radiologist aware of the imaging characteristics of CNS-PTLD and the differential diagnosis can positively impact patient care.

CNS-PTLD cases start presenting within the first year after the immunosuppression with a median time to...
occurrence around 4–5 years [3–7]. However, there are late occurring cases greater than 10 years after the initial transplantation [3–7]. PTLD occurs more frequently in the first year after transplant in patients that are EBV-positive after transplantation, young, EBV-negative prior to transplant, have multi-organ transplants, and have allograft involvement [3–9]. Earlier occurring cases are very likely to be diffuse large B cell lymphoma. With long-term follow-up beyond 10 years, more cases are EBV-negative, T cell lymphomas (especially in renal transplant patients), and there is an association with hepatitis C infection [1, 3–7]. Overall, the vast majority of all cases are diffuse large B cell lymphomas [3]. Old age is associated with later onset PTLD and EBV-negative cases that are more frequently monomorphic. PTLD tends to occur more in children than adults with no gender preference. The incidence of PTLD after solid organ transplant varies by organ. Greater incidences are generally associated with small bowel, lung, and heart/lung, and lower incidences with heart, liver, pancreas, and kidney transplantation [1, 3, 4, 6–8, 10]. Kidney transplant recipients have the highest absolute number of PTLDs which is secondary to the higher number of kidney transplants performed. The difference in incidence among transplant types is likely related to the different immunosuppressive regimes and the amount of EBV-positive lymphocytes in the graft. Also, differences in underlying transplanted organs might confer different levels of chronic antigen stimulation relevant to lymphomagenesis. CNS-PTLD accounts for between 5 and 30% of all PTLD cases. CNS-PTLD patients tend to have poorer survival than patients with PTLD outside of the CNS but given the paucity of CNS-PTLD cases, this analysis is limited. EBV-associated lymphoproliferative disorders can occur in other forms of immunosuppression such as with acquired immune deficiency syndrome (AIDS), and these cases have similar imaging characteristics (Table 1).

The neurological symptoms in CNS-PTLD can be non-specific and are quite variable. The non-specific symptoms include headache, confusional states/mental status changes, and seizure [3, 4]. Headaches are reported as a more common symptom in some studies [3–5]. Also, seizure can present with focal symptoms (e.g., motor, sensory, vision, or memory changes) indicating the lesion location. Reported focal neurological symptoms include hemiparesis, difficulty walking, ataxia, aphasia, dysarthria, facial droop, vertigo, and diplopia [3–5].

It is possible to make the diagnosis of CNS-PTLD with cerebral spinal fluid (CSF) sampling only. Positive CSF PCR for EBV is highly suggestive of the diagnosis and the CSF PCR for EBV can be positive even when PCR on the peripheral blood is negative [11]. Caution is advised in evaluating the CSF by PCR when the blood is positive for EBV. CSF cytological analysis is usually positive in fewer cases but in some small series, a majority of

| Clinical | CNS PTLD | AIDS CNS Lymphoma | PCNS lymphoma |
|----------|----------|-------------------|---------------|
| Lesion number | Multifocal more common than unifocal | Multifocal | Unifocal more common than multifocal |
| Lesion location | Lobar predominantly, numerous basal ganglia and thalamic lesions, less commonly abuts CSF surface | Basal ganglia and corpus callosum | Periventricular, abutting CSF surface |
| Enhancement pattern | Ring | Heterogeneous | Solid |
| Margin of enhancement | Irregular/Ill-defined | Heterogeneous | Homogeneous |
| ADC | Elevated compared to lymphoma, will still have focal areas of restricted diffusion | Slightly elevated compared to normal white matter but lower than in toxoplasmosis | Lower and more homogeneous |
| Perfusion | Limited data, likely overall low (Fig. 2) | Not reported | Low to mildly elevated, leakage pattern very suggestive |
| Spectroscopy | Increased choline, lipid and lactate | Increased choline | Increased choline, lipid and lactate, decrease in NAA, Cr |
| Intratumoral susceptibility signal | Peripheral pattern of punctate hypointensities, tendency to bleed | Decreased NAA | Not reported, there is a tendency to bleed more than PCNS lymphoma |
| | | | Minimal signal changes |
patients have positive CSF cytology [3–5, 7]. Flow cytometric analysis can assist in making the diagnosis of PTLD in the CSF. However, overall, the CSF analysis including CSF cytological analysis usually results in non-specific findings. Biopsy is almost always required for a definitive diagnosis [12].

**Pathology**

CNS-PTLD cases are usually monomorphic by WHO criteria but some cases are polymorphic. Monomorphic CNS-PTLD usually resembles aggressive diffuse large cell lymphomas, nearly always with a B cell phenotype (Fig. 1). CNS-PTLD has a predisposition for growth in the perivascular spaces. These are more common of non-germinal center cell origin, known as the activated B cell-like origin, a subtype that has a worse prognosis. CNS-PTLD of T cell lineage is rare and is seen more frequently in sites outside of the CNS.

**Treatment and survival**

The survival is quite variable with some patients dying within the first month but many patients survive for years [3–7]. The treatment almost invariably involves decreasing or withdrawal of immunosuppressive therapy in the first instance [3, 4, 7, 12]. This must be balanced with not causing rejection of the transplanted organ. Corticosteroids are used routinely. Treatment with chemotherapy or radiotherapy should be strongly considered and the therapies utilized have been rather heterogeneous [3, 4, 7, 12]. However, after multivariate analysis, Cavaliere et al. only found age to be predictive of survival [3]. Methotrexate has more commonly been used intravenously with less common utilization intrathecally [3, 4, 12]. There have also been promising results utilizing rituximab with cranial radiation [13].

There is a trend for improved progression-free survival in patients receiving rituximab and/or cytarabine [7]. More patients are being treated with antiviral therapies with mixed results. Mortality is very high in non-responders to immunosuppressive therapy modification and failures of treatment with first modality [7].

**Imaging**

Identifying the imaging characteristics of CNS-PTLD can aid in the diagnosis and help differentiate CNS-PTLD from several differential diagnostic considerations. A neuroimaging exam can be used to detect the lesion(s), demonstrate the neuroanatomical areas involved, and associated complications such as brain herniation. The MRI or CT examinations should be performed with and without intravenous contrast. Contrast greatly helps to define the lesions in CNS-PTLD. MRI is superior to CT in sensitivity and for detailed analysis of CNS-PTLD lesions. An MRI protocol to best delineate and characterize the brain lesions should include T2-weighted/T2 fluid-attenuated inversion recovery (FLAIR), T1-weighted pre contrast, a gradient-echo or susceptibility-weighted imaging sequence, diffusion-weighted/diffusion tensor imaging (DWI), and the post-contrast T1-weighted images. Perfusion-weighted imaging (PWI) should also be useful to help differentiate CNS-PTLD from other potential diagnostic considerations.

There is a tendency for CNS-PTLD lesions to be ring enhancing, have ill-defined enhancing margins, multifocal, supratentorial, and lobar in location (Figs. 2 and 3) [3–6, 12, 14]. The ring enhancement is secondary to central necrosis, which is a frequent microscopic finding. A partial ring of enhancement appearance has been described [5]. Diffuse enhancement in general is less common but Cavaliere et al. in a large series of 34 patients reported a higher percentage with homogeneous enhancement (41%) or heterogeneous enhancement (56%) and only 29% had ring enhancement [3, 14]. Snanoudj et al. described 87% of cases to have at least one ring-enhancing lesion and all cases to have lesions with enhancement [12]. The contrast enhancement characteristics have not always been mentioned [4, 6, 7].

Numerous authors have found lesions to be multifocal with predominantly lobar location [3, 5, 6, 12]. Predominant multifocal disease has been reported in 61% to 88% cases [3, 5, 6, 12]. An exception is Evens et al. who reported that 63% of cases had one lesion [7]. There is a greater amount of variability with the described location of CNS-PTLD lesions. Evens et al. described a minority of cases to have deep involvement of the basal ganglia, brainstem, cerebellum, and/or periventricular...
involvement [7]. However, the basal ganglia can be frequently involved and even the second most common location (39%) [3, 6]. Although, others have found the periventricular location to be the second most common location and at least one periventricular lesion being seen in 72% of cases [5, 12]. Usually lesions are less commonly reported in the corpus callosum, thalami, and periventricular locations [4–6]. Rarely, lesions are present in isolation in non-lobar locations including infratentorially or in the spinal cord. Rare presentations are generally found to include cerebral lymphomatosis and associated or isolated meningeal contrast enhancing lesions [4]. However, there has been concurrent meningeal enhancement reported in over 50% of patients and meningeal/ependymal enhancement in 40% of patients [3, 5].

The CT density of CNS-PTLD lesions has a wide reported variation. Lesions on CT have been reported to be hyper, iso, or hypointensuating [12, 15, 16]. The presence of hypodensity in the lesions differs from what has been described for PCNS lymphoma [17, 18]. However, mild hyperdensity might be present due to hypercellularity or to the presence of hemorrhage [16, 19].

The data on MRI appearance of CNS-PTLD lesions is limited. The imaging findings reflect lesions that are hypercellular tumors, which are prone to hemorrhage, have cystic and necrotic changes, and surrounding edema. T1-weighted signal intensity has been reported as predominantly hypointense to isointense with few cases having hyperintense or heterogeneous T1 signal [5, 12, 16]. The T1-weighted hyperintense signal likely represents hemorrhage. The solid areas of the masses have relative

---

Fig. 2 CNS-PTLD T1-weighted post-gadolinium images in six cases (a-f). In these cases, the lesions are predominantly ring enhancing. Although, case f has two solid enhancing lesions. There are no solid enhancing periventricular lesions as typically seen in CNS lymphoma. The location of lesions in the basal ganglia in cases c and d would be unusual for metastatic disease.
T2-weighted hypointensity related to hypercellularity but intermediate and increased T2-weighted signal intensities are also seen [16, 19–21]. The cystic and necrotic areas have signal intensities that follow fluid. Given the usually intermixture of solid areas with cystic/necrotic changes, the T2 signal intensities of the lesions are mixed. The T2-weighted images demonstrate well the surrounding edema and the edema around the CNS-PTLD lesions vary from mild to extensive (Fig. 3) [5, 19]. Typically, there is mild edema around small lesions and extensive edema around larger lesions. Susceptibility weighted imaging demonstrates a peripheral pattern of punctate hypointensities that can help discriminate CNS-PTLD from de novo PCNS lymphoma (Fig. 4) [14]. Evidence of hemorrhage or hemosiderin staining was found in five of nine by Lake et al. with one hemorrhage being significant [5].

The solid areas of the lesions often have restricted diffusion likely related to hypercellularity. The diffusion is elevated in the cystic necrotic areas (Fig. 3). This results in appearance with rims of the lesion that have restricted diffusion and scattered areas of restricted diffusion internally where there are areas of hypercellularity (Fig. 3). The apparent diffusion coefficient (ADC) values in CNS-PTLD vs CNS lymphoma are on average higher and more heterogeneous [14]. There is limited literature on gadolinium-based perfusion imaging in CNS-PTLD but low relative CBV ratios have been reported (Fig. 3).
The MR spectroscopic data is very limited for CNS-PTLD [23]. The solid area of enhancement demonstrated elevated choline (Cho), and marked increases in lactate and lipid [23]. In the image from the article by Su et al., the N-acetylaspartate (NAA) is markedly decreased but the authors describe it as preserved [23]. The creatinine (Cr) level is hard to analyze given no normal comparison but has a low appearance. These changes did result in elevated Cho/Cr and decreased NAA/Cho ratios (Fig. 5).

Positron emission tomography (PET)/CT has been used to evaluate CNS-PTLD, although it may be more usefulness for identifying PTLD lesions outside the CNS. CNS lesions on PET/CT are difficult to interpret given the inherent increased uptake of the surrounding brain parenchyma. However, PTLD does show increased SUV uptake on PET, which can help to differentiate between residual tumor and necrosis even in the CNS (Fig. 6) [19]. There can be false positive findings with infectious or inflammatory etiologies. Utilization of PET/CT is likely more beneficial in the follow-up and post treatment setting.

**Differential diagnosis**

The differential diagnosis includes PCNS lymphoma, glioblastoma (GBM), metastatic disease, abscess, or other infection. Infections in transplant patients can include *Aspergillus*, *Nocardia asteroides*, *Toxoplasma gondii*, *Listeria monocytogenes*, Mucorales, Tuberculosis, and less commonly Cryptococcus [24]. Less likely differential diagnostic considerations are tumefactive demyelination, stroke, or neurosarcoidosis. Imaging
characteristics can help narrow the differential diagnosis (Tables 1 and 2).

**PCNS lymphoma**

PCNS lymphoma has many similar features to CNS-PTLD but there are a number of differences (Table 1). PCNS lymphoma compared to CNS-PTLD has more diffuse and homogeneous enhancement with well-defined margins of enhancement (Figs. 5 and 7) [14, 25]. Less frequent types of enhancement for PCNS lymphoma are “open-ring-like” enhancement, ring enhancement, and notch enhancement. The lesions tend to involve a CSF or pial surface (80–90%) more commonly than in CNS-PTLD (Figs. 5 and 7). PCNS lymphoma is one of the two main mass lesions that typically involve the corpus callosum, the other lesion being GBM. The lesions in PCNS lymphoma have a predominance of being unifocal but can be multifocal with Sutherland et al. reporting more multifocal cases [25, 26]. The signal intensities on T1 and T2 have been reported as similar to CNS-PTLD [26]. When unifocal, the lesions were significantly larger [25]. The frontal lobes and corpus callosum are commonly involved and the presence of lesions in the basal ganglia and posterior fossa are infrequent (either isolated or associated with supratentorial

| Table 2 How to differentiate CNS PTLD from other pathologies |
|------------------|------------------|
| **GBM**          | **Abscess**      |
| High perfusion in the enhancing mass | High diffusion signal centrally with relative restricted ADC |
| More commonly will be a single enhancing lesion, around 2/3 of the time | Low diffusion signal in the rim with elevated ADC |
| More common involvement of the corpus callosum | Thin smooth rim of enhancement with thin rim of low T2 signal |
| Peritumoral region can have abnormalities indicating tumor (increased perfusion, restricted diffusion, tumor spectroscopy) | Smooth rim of hypointensity on susceptibility weighted images |
| | Spectroscopy—amino acids present in the abscess cavity (valine, leucine and isoleucine; 0.9 ppm), acetate (1.9 ppm), alanine (1.5 ppm), and succinate (2.4 ppm)) |
| **Metastatic disease** |                  |
| High perfusion in the enhancing mass | High perfusion in the enhancing mass |
| Tend not to occur in the basal ganglia, thalami, or periventricular locations |
disease), contrasting with CNS-PTLD. Leptomeningeal disease is rare but possible and edema is a common finding, both similar to CNS-PTLD. The presence of calcification or hemorrhage is uncommon. In fact, the lack of intratumoral susceptibility signals (ITSS) changes helps differentiate lymphoma from CNS-PTLD, GBM, or metastatic disease [14, 27].

A common signature feature of PCNS lymphoma is marked associated restricted diffusion in the mass lesions secondary to hypercellularity. The ADC values in PCNS lymphoma are typically lower and more homogeneous than in CNS-PTLD [14]. The ADC and FA values measured in the solid enhancing components of lymphoma are significantly decreased compared to GBM [28]. The perfusion of PCNS lymphomas are relatively low with reported rCBVs $1.29 \pm 0.18$ to $2.74 \pm 0.87$ [29–31]. The variation in the rCBVs measured likely relates to the analysis technique but the rCBV values are consistently found to be significantly lower than in high-grade gliomas. The signal recover of the perfusion curve is also significantly higher (rising above baseline) in PCNS lymphoma than in high-grade gliomas [31–33]. This leakage pattern does not prove PCNS lymphoma but it is an important diagnostic clue [33]. Spectroscopy can show the presence of lipid and/or lactate, increased Cho/Cr, and decreased NAA/Cho [34]. However, this pattern can be seen with GBM and metastatic disease. A massively elevated lipid peak and a markedly elevated Cho/Cr ratio has been found to be more suggestive of PCNS lymphoma than glioma [35]. The spectral pattern might help to differentiate from abscesses which often demonstrate a number of amino acids peaks not seen in PCNS lymphoma.

**Glioblastoma**

Glioblastoma (GBM) WHO grade IV is the most common primary intraparenchymal tumor, is typically ring enhancing, and can have a similar appearance to CNS-PTLD. GBM mostly occurs in the cerebral hemispheres and rarely in the posterior fossa or spinal cord. GBMs are a common mass lesion to involve the corpus callosum and this is a less common characteristic of CNS-PTLD. Predominantly, GBMs presents as single masses but multifocal or multicentric disease can occur around 33% of the time. Typically, GBM presents as a large heterogeneous mass with central necrosis and concave shaggy enhancing margin. GBMs occur in all age groups but has a peak incidence in the 7th and 8th decades. GBM is a diagnostic consideration for many ring-enhancing brain lesions with surrounding edema as seen with CNS-PTLD. However, GBM can infrequently present as a solid enhancing mass with necrosis only present at pathological analysis. ITSS signal changes are often found in GBMs and could represent...
Fig. 8 Glioblastoma. T1-weighted image with gadolinium (a) shows an irregular rim-enhancing mass with thick (arrowheads) and thin (long arrows) areas of enhancement in the right frontal lobe. The mass extends into the genu of the corpus callosum and left frontal lobe with minimal irregular enhancement (short arrows). ADC map (b) demonstrates predominant elevated ADC within the necrotic mass. The rim of the mass has minimal decreased ADC values (arrows). T2 FLAIR (c) shows the necrotic right frontal lobe mass, enlargement of the genu of the corpus callosum and diffuse mild T2 high signal abnormality in the left frontal lobe. On CBV map (d, e), there is associated increased perfusion in the rim of the mass (long arrows) in the right frontal lobe, corpus callosum (short arrow), and to a lesser degree in the left frontal lobe (arrowheads).
microhemorrhages or calcifications [27]. Massive hemorrhage can occur and this will obscure the underlying tumor.

The solid component of GBM in general demonstrates elevated rCBV, and elevated ADC values [32, 36]. Where there is hypercellularity, ADC values will be decreased. The FA and ADC values in lymphoma are usually lower than in GBM, likely reflecting greater relative cellularity of PCNS lymphoma [28]. A leakage pattern of the contrast enhancement curve occurs with GBM but not as frequently as in PCNS lymphoma. MR spectroscopy in GBM usually demonstrates elevated lipids and/or lactate, elevated Cho/Cr ratios, and low NAA/Cho ratios. Important imaging findings that favor a diagnosis of GBM are biomarkers that are positive outside of the area of enhancement (the peritumoral area). The ADC might be restricted, the CBV elevated, and the spectroscopy values can indicate tumor in areas outside of enhancing abnormalities in GBM given its infiltrative nature (Fig. 8) [37–40]. The peritumoral area of GBM has been found to have decreased ADC compared to PCNS lymphoma [40]. This relationship would be expected to be present in CNS-PTLD.

Abscess
CNS pyogenic abscesses if hematogenously spread occur supratentorially and in subcortical locations [41]. When abscess occurs secondary to direct extension, the abscess is adjacent to where it originated such as the paranasal sinuses or the temporal bone. Abscesses are more commonly single than multiple, which is the opposite of CNS-PTLD lesions. However, abscesses are more likely to be multiple in the immunosuppressed patient. CNS pyogenic abscesses are round or oval with a thin smooth rim of enhancement. The characteristics of the enhancing wall can help differentiate an abscess from CNS-PTLD in which the walls are thicker and more irregular. The abscess capsule may be seen as a thin band of T2 hypointensity that is relatively specific for abscess (Fig. 9) [41]. Susceptibility-weighted
imaging in a pyogenic abscess can demonstrate a thin rim of hypointensity or dual-rim sign but in fungal abscesses, one finds a prominent peripheral rim or central susceptibility effects [42, 43]. These appearances are different than for CNS-PTLD which demonstrates a peripheral pattern of punctate susceptibility-weighted hypointensities.

DWI and ADC analysis of the abscess cavity are also very useful [44–47]. Abscesses tend to have cavities of relative restricted ADC and high diffusion signal, whereas the necrotic cavities of tumors have higher ADC values [47]. The opposite is true for the rims of these lesions with higher ADC values in the rims of abscesses and lower ADC values in the rims of tumors. The diffusion characteristics of the rims of abscesses and tumors offer the better diagnostic differentiation between these entities. The reason is even though the central cavities of tumors usually have lower signal on DWI

---

**Fig. 10** Cerebral toxoplasmosis. T1-weighted image with gadolinium (a) shows multiple ring and nodular-enhancing masses in the basal ganglia. T2-weighted image (b) shows extensive edema. No obvious restricted diffusion in the lesions is present on the ADC map (c). Single voxel spectroscopy (TE = 35) (d) demonstrates elevated lipid/lactate peak (arrow) and all other peaks are decreased.
and elevated ADC values, the presence of hemorrhage and the debris within necrotic components of tumors can result in elevated DWI signal and lower ADC values that mimic the appearance of an abscess.

On PWI, abscesses typically have mildly elevated CBV [44, 46, 48, 49]. This makes PWI less useful for differentiating an abscess from lymphoma or likely CNS-PTLD. The abscess MR spectrum does not have elevated choline but has elevated amino acids from 0.9–2.4 ppm (valine, leucine and isoleucine; 0.9 ppm), acetate (1.9 ppm), alanine (1.5 ppm), and succinate (2.4 ppm)) [46]. This spectrum when present helps identify an abscess cavity.

Neurotoxoplasmosis, an opportunistic infection, is the most common cause of cerebral abscess in immunocompromised patients. Like CNS-PTLD, cerebral toxoplasmosis tends to present as multiple lesions in the basal ganglia and at the corticomedullary junctions. These lesions are characterized by a ring or nodular enhancement, so it must be considered in a differential diagnosis of CNS-PTLD. Toxoplasmosis on MR spectroscopy often shows increased lactate and lipids and reduced Cho, Cr, and NAA (Fig. 10) [50].

Metastatic disease

The imaging characteristics of metastatic disease overlap significantly with CNS-PTLD. Many cases of metastatic disease in the brain are ring enhancing with multiple lobar lesions but single metastatic brain lesions are not uncommon. These features are similar to CNS-PTLD. However, metastatic disease is not as commonly present in the basal ganglia, thalami, and periventricular locations as CNS-PTLD. CNS-PTLD and metastatic disease both often have ring enhancement that is heterogeneous. PCNS lymphoma is a usually a more solid homogeneously enhancing disease process.
The DWI and spectral appearance of metastatic disease and CNS-PTLD are expected to be similar with no comparisons having been made directly between these disease processes. Metastatic disease has tumor spectroscopy findings of decreased NAA/Cho, elevated Cho/Cr, and presence of lipid and lactate [39]. Lymphomas do tend to have more restricted diffusion than metastatic disease. However, a hypercellular metastatic lesion would likely have lower ADC values that could be similar to lymphoma. PWI should likely help to differentiate metastatic disease since metastatic lesions usually have high perfusion and lymphomas do not. This is expected to hold true for CNS-PTLD but perfusion data on CNS-PTLD is very limited (Fig. 3) [22]. Perfusion, DWI/ADC, and spectroscopy analysis can be confounded by the presence of extensive necrosis or hemorrhage obscuring the metastatic disease. Both CNS metastatic disease and CNS-PTLD should not have peritumoral changes that have characteristics of tumor such as seen with GBM (Fig. 11) [37–40].

Conclusion

CNS-PTLD is a complicated disease process that affects immunosuppressed post-transplant individuals. Being able to accurately help differentiate this diagnosis through imaging is vital and helps optimize making an early diagnosis (Tables 1 and 2). Given the rarity of the diagnosis, the consideration of CNS-PTLD is often lacking on initial imaging interpretations. Advanced imaging characteristics likely will help to diagnosis CNS-PTLD but our review of the literature demonstrates a paucity of information pertaining to these techniques. CNS-PTLD shares imaging characteristics with multiple other disease processes including PCNS lymphoma, GBM, metastatic disease, abscess, and other infections. Even though definitive diagnosis will often come down to biopsy, imaging characteristics will help distinguish the disease processes.

Acknowledgements

We thank Dr. Justin Cramer for his thoughtful proofreading and insightful suggestions.

Authors’ contributions

All authors read and approved the final manuscript.

Competing Interests

The authors declare that they have no competing interests.

Ethics approval and consent to participate

Institutional review board approved this study.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
19. Borhani AA, Hosseinazdeh K, Almus A, Furtan A, Nalesnik M (2009) Imaging of posttransplantation lymphoproliferative disorder after solid organ transplantation. Radiographics 29(4):981–1000
20. Camacho JC, Moreno CC, Hanis PA, Aguirre DA, Torres WE, Mittal PK (2014) Posttransplantation lymphoproliferative disease: proposed imaging classification. Radiographics 34(7):2025–2038
21. Mendelton M, Barday Z, Eastman R et al (2012) Rapidly progressive post-transplant lymphoproliferative disease following withdrawal of sirolimus. S Afr Med J 102(12):924–926
22. Lapucci C, M F, Boffa G et al (2016) Very-late onset primary CNS post-transplant lymphoproliferative disease (PTLD): report of three cases and literature review. In: Congresso Nazionale 22–25 Ottobre 2016, Venezia
23. Su IC, Lien HC, Chen CM (2006) Primary brain T-cell lymphoma after kidney transplantation: a case report. Surg Neurol 66:560–563
24. Moscato M, Boon-Unge K, Restrepo L (2013) Enhancing brain lesions in a transplant patient. Neurohospitalist 3(1):15–19
25. Zhang D, Hu LB, Henning TD et al (2010) MRI findings of primary CNS lymphoma in 26 immunocompetent patients. Korean J Radiol 11(3):269–277
26. Sutherland T, Yap K, Liew E, Tartaglia C, Pang M, Trost N (2012) Primary central nervous system lymphoma in immunocompetent patients: a retrospective review of MR features. J Med Imaging Radiat Oncol 56(3):295–301
27. Kim HS, Jahng GH, Ryu CW, Kim SY (2009) Added value and diagnostic performance of intratumoral susceptibility signals in the differential diagnosis of solitary enhancing brain lesions: preliminary study. AJNR Am J Neuroradiol 29(3):471–475
28. Toh CH, Castillo M, Wong AM et al (2008) Primary cerebral lymphoma and glioblastoma multiforme: differences in diffusion characteristics evaluated with diffusion tensor imaging. AJNR Am J Neuroradiol 29(3):471–475
29. Lee H, Kim ST, Kim HJ, Kim KH, Jeon P, Byun HS (2010) Analysis of perfusion weighted image of CNS lymphoma. Eur J Radiol 76(1):48–51
30. Nakajima S et al (2015) Differentiation between primary central nervous system lymphoma and glioblastoma: a comparative study of parameters derived from dynamic susceptibility contrast-enhanced perfusion-weighted MRI. Clin Radiol 70(12):1393–1399
31. Hartmann M, Heiland S, Harting I et al (2003) Distinguishing of primary cerebral lymphoma from high-grade glioma with perfusion-weighted magnetic resonance imaging. Neurosci Lett 338(2):119–122
32. Xing Z, You RX, Li J, Liu Y, Cao DR (2014) Differentiation of primary central nervous system lymphoma from high-grade gliomas by rCBV and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Clin Neuroradiol 24(4):329–336
33. Jensen-Kondering U, Henker C, Dörner L, Hugo HH, Jansen O (2012) Differentiation of primary central nervous system lymphomas from high grade astrocytomas by qualitative analysis of the signal intensity curves derived from dynamic susceptibility-contrast magnetic resonance imaging. Neurol Res 34(10):984–988
34. Raizer JJ, Koutcher JA, Abrey LE et al (2005) Proton magnetic resonance spectroscopy in immunocompetent patients with primary central nervous system lymphoma. J Neurooncol 71(2):173–180
35. Harting I, Hartmann M, Jost G et al (2003) Differentiating primary central nervous system lymphoma from glioma in humans using localised proton magnetic resonance spectroscopy. Neurosci Lett 342(1):163–166
36. Hakymzene B, Erdogan C, Yildirim N, Parlak M (2005) Glioblastoma multiforme with atypical diffusion-weighted MR findings. Br J Radiol 78(935):989–992
37. Law M, Cha S, Knopp E, Johnson G, Arnett J, Litt AW (2002) High-grade gliomas and solitary metastases: differentiation by using perfusion and proton spectroscopic MR imaging. Radiology 222(3):715–721
38. Tsalaki E, Svolos P, Kouss E et al (2013) Automated differentiation of glioblastomas from intracranial metastases using 3T MR spectroscopic and perfusion data. Int J Comput Assist Radiol Surg 8(5):751–761
39. Tsougos I, Svolos P, Kouss E et al (2012) Differentiation of glioblastoma multiforme from metastatic brain tumor using proton magnetic resonance spectroscopy, diffusion and perfusion metrics at 3 T. Cancer Imaging 12(3):423–436
40. Ko CC, Tai MH, Li CF et al (2016) Differentiation between glioblastoma Multiforme and primary cerebral lymphoma: additional benefits of quantitative diffusion-weighted MR imaging. PLoS One 11(9):e0162565